Pancreatic
Back to Oncology/Cancer Clinical Trials Main PageCPMC Cancer Services
| Principal Investigator/Contact Information | Protocol Title | Patient Population | Recruitment Period |
| Principal Investigator: CPMC Oncologists Contact: Brenda Eng 415-600-1775 | A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) + Gemcitabine + Erlotinib as 1st Line Treatment in Patients with Metastatic Pancreatic Cancer (SWOG 0727) Visit this study on ClinicalTrials.gov. | Patients with pancreatic cancer that has spread to other parts of your body. | Open |
| Principal Investigator: Ari Baron, MD Contact: Rich Sommers 415-600-1578 | A Phase II Study of Hyperacute®-Pancreatic Cancer Vaccine in subjects with surgically resected Pancreatic Cancer. NewLink Genetics NLG0205 Visit this study on ClinicalTrials.gov. | Subjects with Pancreatic Cancer | Open |
updated: 11/18/09
Back to top